Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X1LO
|
|||
| Former ID |
DIB016292
|
|||
| Drug Name |
EMR-62203
|
|||
| Synonyms |
EMR-6203; PDE 5 inhibitor, Merck KGaA
Click to Show/Hide
|
|||
| Indication | Erectile dysfunction [ICD-11: HA01.1; ICD-10: N48.4; ICD-9: 302.72, 607.84] | Discontinued in Phase 2 | [1] | |
| Company |
Merck KGaA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 5A (PDE5A) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Purine metabolism | |||
| cGMP-PKG signaling pathway | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Reactome | cGMP effects | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018868) | |||
| REF 2 | WO patent application no. 2006,0180,88, Use of a pde 5 inhibitor for treating and preventing hypopigmentary disorders. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.